Two GLP-1 Pills, Two Approaches: Why One Is a Peptide and One Isn’t
Peptides are usually injected because the gut breaks them down
Most peptide medicines, including insulin and injectable semaglutide, are given by injection. A 2022 review by Aroda, Blonde and Pratley explains why: peptides with a molecular weight above 1,000 daltons face “enzymatic degradation in the GI tract, pH-induced conformational changes, limited permeability of the intestinal membrane,” along with low permeability of the gut wall to peptides [1]. In short, digestive enzymes chew them up, and what survives struggles to cross the intestinal lining.
That background is why two newly approved weight-loss pills are scientifically interesting. They solve the same problem in opposite ways.
The Wegovy pill keeps the peptide and adds an absorption enhancer
On December 22, 2025, FDA approved the Wegovy pill, a once-daily oral form of semaglutide, which Novo Nordisk describes as the first oral GLP-1 receptor agonist approved for weight management [2]. The current label covers two uses in adults: lowering the risk of major cardiovascular events in people with established cardiovascular disease and obesity or overweight, and reducing excess body weight and keeping it off, alongside diet and physical activity [3].
The tablet contains salcaprozate sodium (SNAC), an absorption enhancer that the injection does not include [3]. Even so, absorption is small. The Aroda review reports oral semaglutide bioavailability of 0.8% under recommended dosing conditions, rising to about 1.4% with a much longer post-dose fast, and high variability between doses within the same person [1]. The label’s administration rules reflect this: the tablet must be taken on an empty stomach with only a small amount of water, followed by a waiting period before eating, drinking or taking other oral medicines [3].
Human evidence for the Wegovy pill: the OASIS 4 trial
OASIS 4 was a phase 3, randomized, placebo-controlled trial published in the New England Journal of Medicine in 2025. It enrolled 307 adults with overweight or obesity and without diabetes: 205 received oral semaglutide and 102 received placebo, with lifestyle support in both groups [4]. The trial ran 71 weeks, including 64 weeks of treatment [4].
At week 64, the estimated mean weight change was about −14% with oral semaglutide versus −2% with placebo. Thirty percent of the oral semaglutide group lost 20% or more of body weight, compared with 3% on placebo [4]. Gastrointestinal side effects were more common with the drug (74% versus 42%), and 7% of the oral semaglutide group stopped because of adverse events versus 6% on placebo [4]. Novo Nordisk’s own release cites 16.6% weight loss, but that figure counts people who adhered to treatment, a different way of counting from the −14% above [2, 4].
Foundayo avoids the peptide problem by not being a peptide
FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in adults with obesity, or with overweight plus a weight-related condition [5]. Eli Lilly describes it as a “once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist” that can be taken without restrictions on food and water [6]. The label says it can be taken with or without food [7]. FDA noted it was the first new molecular entity approved under its national priority voucher program, with a decision issued 50 days after filing [5].
Because it is a small molecule rather than a peptide chain, it does not need an absorption enhancer or a fasting routine. That is a chemistry difference, not a proven difference in outcomes.
FDA’s approval announcement quoted agency official Høeg describing it as “a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach” [5]. The Wegovy tablet label includes a cardiovascular-event indication [3]; in the sources we reviewed, we found no cardiovascular outcomes data for Foundayo, so that difference in labeled uses is worth noting.
Human evidence for Foundayo: the 72-week ATTAIN-1 trial
The Foundayo label describes a 72-week, placebo-controlled trial in adults without type 2 diabetes (NCT05869903). Among 949 people on placebo, average weight change was −2.1%. At the highest dose studied (730 people) it was −11.1%, a placebo-adjusted difference of about 9 percentage points [7]. Lilly reports a larger figure, 12.4% versus 0.9%, for participants who stayed on treatment [6]. As with the Wegovy pill, the two ways of counting answer different questions.
Across the two trials in the label, 8% of people taking Foundayo permanently stopped because of adverse reactions, versus 3% on placebo, mostly from gastrointestinal effects (5%) [7]. Common side effects include nausea, constipation, diarrhea and vomiting [5].
Animal and lab evidence shapes the warnings
Both labels carry a boxed warning about thyroid C-cell tumors, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [3, 7]. The evidence behind the warning differs. Animal findings can flag a risk, but they cannot settle it for people.
- Semaglutide (animal evidence). It causes thyroid C-cell tumors in rodents, and it is unknown whether it does so in humans [3].
- SNAC (animal evidence). In rats, SNAC crosses the placenta, and SNAC or its metabolites are present in human milk, so the label advises against breastfeeding during treatment [3].
- Orforglipron (animal evidence). The label says it is not pharmacologically active in rats or mice and did not cause tumors in rodent studies, so those studies cannot answer the human question. Its relevance to humans has not been determined [7].
Other label warnings are similar, and neither pill is combined with another GLP-1
FDA’s approval announcement for Foundayo lists warnings for pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, low blood sugar, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, acute gallbladder disease and aspiration during anesthesia or deep sedation. It should not be combined with another GLP-1 receptor agonist [5]. The Wegovy label likewise does not recommend using the tablets with other semaglutide products or other GLP-1 receptor agonists [3]. These are summaries; the full labels and a prescriber are the place to check personal risk.
Why two trial results cannot be lined up as a ranking
It is tempting to compare −14% with −11.1%. The sources do not support that. The trials differ in size (307 versus about 3,100 participants across the Foundayo arms in the label’s table), length (64 versus 72 weeks), dose arms and the way results are counted. We found no head-to-head trial of the two pills in the sources reviewed. OASIS 4 participants were also a fairly narrow group, 79% women, 92% White, with a mean age of 48, so results may not describe everyone [4]. The right takeaway is narrower: both have randomized placebo-controlled human data and FDA approval, and both come with a boxed warning and frequent stomach-related side effects.
For more on semaglutide’s wider evidence, see our semaglutide profile, and tirzepatide for the injectable dual-agonist.
What this means for unapproved oral peptides
The Wegovy pill needed a dedicated absorption enhancer, and its bioavailability is still only about one percent [1]. That context helps when reading about oral versions of unapproved peptides. In its recent compounding policy, HHS requires that oral compounded peptide products come with documentation that the formulation achieves adequate oral bioavailability in humans [8]. We cover that notice in our explainer on the HHS peptide policy. A peptide labelled as oral is not shown to work by the label alone.
Frequently asked questions
Is Foundayo (orforglipron) a peptide?
No. Eli Lilly describes it as a small molecule (non-peptide) that acts on the GLP-1 receptor [6].
Why does the Wegovy pill need to be taken on an empty stomach?
The label requires an empty stomach, a small amount of water and a waiting period before eating, drinking or other oral medicines [3]. The Aroda review reports that absorption is low and that larger water volumes reduced it, which is consistent with strict rules [1].
Are the pills as effective as the injections?
The sources we reviewed do not include a head-to-head comparison of the pills with injections, so we cannot say. OASIS 4 and ATTAIN-1 each compared a pill with placebo [4, 7].
Who should not take these medicines?
Both labels carry a boxed warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. A prescriber can review other warnings [3, 7].
Do compounded oral peptides work the same way?
That has not been shown by the sources we reviewed. HHS’s policy asks compounders to document adequate oral bioavailability for oral products, which implies it is not assumed [8].
Sources
Every factual claim in this article comes from a source we opened and read while writing it. Where a source is a news or law-firm summary, we say so in the text.
- Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide. Rev Endocr Metab Disord. 2022;23(5):979-994
- Novo Nordisk: FDA approves Wegovy pill (Dec. 22, 2025)
- FDA prescribing information: Wegovy (semaglutide) injection and tablets, revised 06/2026
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393(11):1077-1087 (summary: ACC Journal Scan)
- FDA press release: FDA approves first new molecular entity under National Priority Voucher program (Foundayo), April 1, 2026
- Eli Lilly: FDA approves Foundayo (orforglipron), the only GLP-1 pill (April 1, 2026)
- DailyMed: Foundayo (orforglipron) prescribing information, revised 7/2026
- Venable: HHS Announces Interim Enforcement Discretion for Section 503A Compounding with Certain Peptide Bulk Drug Substances (Nov. 6, 2026)
Medical disclaimer
Peptides.rodeo is for education only and is not medical advice. Nothing on this site is meant to diagnose, treat, cure or prevent any disease, or to replace a consultation with a licensed physician or pharmacist.
Many compounds described here are not approved by the U.S. Food and Drug Administration for human use. Products sold “for research use only” may be mislabelled, contaminated or of unknown strength. We do not publish dosing protocols for unapproved compounds, and we do not sell, source or recommend vendors.
Evidence grades summarise published research at the date shown and can change as new studies appear. Always talk to a qualified healthcare provider before starting, stopping or changing any medication or supplement, especially if you are pregnant, nursing, have a medical condition or take other medicines. If you think you are having a medical emergency, call 911 or your local emergency number.
Written by Peptides.rodeo Editorial. This article has not been reviewed by a clinician and is not medical advice. We take no money from peptide vendors and use no affiliate links.